Publications dans lesquelles il/elle collabore avec Susana Ravassa Albéniz (24)

2024

  1. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart

2023

  1. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides

    JACC: Heart Failure, Vol. 11, Núm. 1, pp. 58-72

2022

  1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

2020

  1. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

    Nefrologia, Vol. 40, Núm. 3, pp. 223-236

2017

  1. Hypertensive Heart Disease

    Encyclopedia of Cardiovascular Research and Medicine (Elsevier), pp. 517-526

  2. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites

    Scientific Reports, Vol. 7

  3. The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes

    Medical Clinics of North America, Vol. 101, Núm. 1, pp. 43-52

2016

  1. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure

    Journal of the American College of Cardiology, Vol. 67, Núm. 3, pp. 251-260

  2. Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients

    Clinical Science, Vol. 130, Núm. 23, pp. 2139-2149

2015

  1. Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study

    International Journal of Cardiology, Vol. 185, pp. 177-185

  2. Circulating biomarkers of myocardial fibrosis: The need for a reappraisal

    Journal of the American College of Cardiology, Vol. 65, Núm. 22, pp. 2449-2456

2013

  1. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients

    Journal of Hypertension, Vol. 31, Núm. 3, pp. 587-594

2001

  1. Cardiomyocyte apoptotic cell death in arterial hypertension: Mechanisms and potential management

    Hypertension

  2. Marcadores bioquímicos de fibrosis miocárdica en las enfermedades cardíacas

    Hipertensión y Riesgo Vascular, Vol. 18, Núm. 8, pp. 383-388

  3. Vascular oxidative stress and endothelial dysfunction

    Nefrología : publicación oficial de la Sociedad Española Nefrologia, Vol. 21 Suppl 1, pp. 61-66

2000

  1. Beneficial aspects of vascular apoptosis in hypertensive heart disease

    Journal of Clinical and Basic Cardiology, Vol. 3, Núm. 1, pp. 61-62

  2. Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats

    Hypertension, Vol. 36, Núm. 6, pp. 1065-1071

1999

  1. Apoptosis of cardiomyocytes in arterial hypertension

    CARDIOVASCULAR RISK FACTORS, Vol. 8, Núm. 5, pp. 257 - 263

  2. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats

    Hypertension, Vol. 34, Núm. 1, pp. 138-143